· Gefitinib Gefitinib 1. Non-small cell lung cancer EGFR DNA EGF-R exon 19 deletion, exon 21...

19

Transcript of  · Gefitinib Gefitinib 1. Non-small cell lung cancer EGFR DNA EGF-R exon 19 deletion, exon 21...

Page 1:  · Gefitinib Gefitinib 1. Non-small cell lung cancer EGFR DNA EGF-R exon 19 deletion, exon 21 [1.858R] substitution mutations, L861Q G719X EGFR exon 20
Page 2:  · Gefitinib Gefitinib 1. Non-small cell lung cancer EGFR DNA EGF-R exon 19 deletion, exon 21 [1.858R] substitution mutations, L861Q G719X EGFR exon 20
Page 3:  · Gefitinib Gefitinib 1. Non-small cell lung cancer EGFR DNA EGF-R exon 19 deletion, exon 21 [1.858R] substitution mutations, L861Q G719X EGFR exon 20
Page 4:  · Gefitinib Gefitinib 1. Non-small cell lung cancer EGFR DNA EGF-R exon 19 deletion, exon 21 [1.858R] substitution mutations, L861Q G719X EGFR exon 20
Page 5:  · Gefitinib Gefitinib 1. Non-small cell lung cancer EGFR DNA EGF-R exon 19 deletion, exon 21 [1.858R] substitution mutations, L861Q G719X EGFR exon 20
Page 6:  · Gefitinib Gefitinib 1. Non-small cell lung cancer EGFR DNA EGF-R exon 19 deletion, exon 21 [1.858R] substitution mutations, L861Q G719X EGFR exon 20
Page 7:  · Gefitinib Gefitinib 1. Non-small cell lung cancer EGFR DNA EGF-R exon 19 deletion, exon 21 [1.858R] substitution mutations, L861Q G719X EGFR exon 20
Page 8:  · Gefitinib Gefitinib 1. Non-small cell lung cancer EGFR DNA EGF-R exon 19 deletion, exon 21 [1.858R] substitution mutations, L861Q G719X EGFR exon 20
Page 9:  · Gefitinib Gefitinib 1. Non-small cell lung cancer EGFR DNA EGF-R exon 19 deletion, exon 21 [1.858R] substitution mutations, L861Q G719X EGFR exon 20
Page 10:  · Gefitinib Gefitinib 1. Non-small cell lung cancer EGFR DNA EGF-R exon 19 deletion, exon 21 [1.858R] substitution mutations, L861Q G719X EGFR exon 20
Page 11:  · Gefitinib Gefitinib 1. Non-small cell lung cancer EGFR DNA EGF-R exon 19 deletion, exon 21 [1.858R] substitution mutations, L861Q G719X EGFR exon 20
Page 12:  · Gefitinib Gefitinib 1. Non-small cell lung cancer EGFR DNA EGF-R exon 19 deletion, exon 21 [1.858R] substitution mutations, L861Q G719X EGFR exon 20
Page 13:  · Gefitinib Gefitinib 1. Non-small cell lung cancer EGFR DNA EGF-R exon 19 deletion, exon 21 [1.858R] substitution mutations, L861Q G719X EGFR exon 20
Page 14:  · Gefitinib Gefitinib 1. Non-small cell lung cancer EGFR DNA EGF-R exon 19 deletion, exon 21 [1.858R] substitution mutations, L861Q G719X EGFR exon 20
Page 15:  · Gefitinib Gefitinib 1. Non-small cell lung cancer EGFR DNA EGF-R exon 19 deletion, exon 21 [1.858R] substitution mutations, L861Q G719X EGFR exon 20
Page 16:  · Gefitinib Gefitinib 1. Non-small cell lung cancer EGFR DNA EGF-R exon 19 deletion, exon 21 [1.858R] substitution mutations, L861Q G719X EGFR exon 20
Page 17:  · Gefitinib Gefitinib 1. Non-small cell lung cancer EGFR DNA EGF-R exon 19 deletion, exon 21 [1.858R] substitution mutations, L861Q G719X EGFR exon 20
Page 18:  · Gefitinib Gefitinib 1. Non-small cell lung cancer EGFR DNA EGF-R exon 19 deletion, exon 21 [1.858R] substitution mutations, L861Q G719X EGFR exon 20
Page 19:  · Gefitinib Gefitinib 1. Non-small cell lung cancer EGFR DNA EGF-R exon 19 deletion, exon 21 [1.858R] substitution mutations, L861Q G719X EGFR exon 20

SUMMIT (PUMA-NER-5201) Basket Trial...5 SUMMIT study design for EGFR exon 18mutant lung cancer cohort EGFR exon 18-positive Lung Cancer Neratinib monotherapy (240 mg, oral daily) Clinical

SUMMIT (PUMA-NER-5201) Basket Trial...5 SUMMIT study design for EGFR exon 18mutant lung cancer cohort EGFR exon 18-positive Lung Cancer Neratinib monotherapy (240 mg, oral daily) Clinical

GENEFLASH - · PDF filePilihan Terapi Oleh Najmiatul ... gen EGFR terletak pada domain kinase tirosin, umumnya berupa in-frame deletion pada exon 19 dan ... HIV, dan sebagainya

GENEFLASH - · PDF filePilihan Terapi Oleh Najmiatul ... gen EGFR terletak pada domain kinase tirosin, umumnya berupa in-frame deletion pada exon 19 dan ... HIV, dan sebagainya

PMDA Perspectives on CDx · EGFR mutation detection kit approved in Japan RAPS2019 CDx gefitinib erlotinib afatinib osimertinib dacomitinib Therascreen EGFR mutation detection kit

PMDA Perspectives on CDx · EGFR mutation detection kit approved in Japan RAPS2019 CDx gefitinib erlotinib afatinib osimertinib dacomitinib Therascreen EGFR mutation detection kit

Molecular Cancer - RESEARCH Open Access Synergistic ......EGFR, including low molecular weight tyrosine kinase inhibitors [22]. Gefitinib (Iressa, ZD-1839) acts as a competitive inhibitor

Molecular Cancer - RESEARCH Open Access Synergistic ......EGFR, including low molecular weight tyrosine kinase inhibitors [22]. Gefitinib (Iressa, ZD-1839) acts as a competitive inhibitor

Next-Generation EGFR Tyrosine Kinase Inhibitors for ... · gefitinib in the first-line treatment of patients with EGFR-mutant NSCLC (15). Unfortunately, the majority of patients progress

Next-Generation EGFR Tyrosine Kinase Inhibitors for ... · gefitinib in the first-line treatment of patients with EGFR-mutant NSCLC (15). Unfortunately, the majority of patients progress

Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to … · exon 20 mutations were identified (Table 1). The most common mutation resulted in a duplication of codon 772

Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to … · exon 20 mutations were identified (Table 1). The most common mutation resulted in a duplication of codon 772

Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon ......Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer Francois

Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon ......Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer Francois

NSCLC Progress in the treatment Optimal Treatment with EGFR-TKI Therapy Gefitinib vs. Erlotinib 蔡 俊 明 Chun-Ming Tsai, MD Section of Thoracic Oncology Chest.

NSCLC Progress in the treatment Optimal Treatment with EGFR-TKI Therapy Gefitinib vs. Erlotinib 蔡 俊 明 Chun-Ming Tsai, MD Section of Thoracic Oncology Chest.

EGFR exon 20 insertion mutations and response to osimertinib in … · 2019. 8. 15. · NSCLC cases. The most frequently identified EGFRexon20ins is A767_V769dup (17/53,32.1%). We

EGFR exon 20 insertion mutations and response to osimertinib in … · 2019. 8. 15. · NSCLC cases. The most frequently identified EGFRexon20ins is A767_V769dup (17/53,32.1%). We

Next Generation EGFR Inhibitors - Amazon S3 · The Chinese University of Hong Kong. EGFR TKIs First Generation-Gefitinib ... Osimertinib approved by FDA on Nov 13, ... Yang et al

Next Generation EGFR Inhibitors - Amazon S3 · The Chinese University of Hong Kong. EGFR TKIs First Generation-Gefitinib ... Osimertinib approved by FDA on Nov 13, ... Yang et al

Gefitinib Iressa Anticancer Medicine

Gefitinib Iressa Anticancer Medicine

CARE™ Lung Cancer AACR 2020 Update - careeducation.ca › wp-content › uploads › 2020 › ... · CARE™ Lung Cancer AACR 2020 Update Target: EGFR Exon 20 Insertion Poziotinb

CARE™ Lung Cancer AACR 2020 Update - careeducation.ca › wp-content › uploads › 2020 › ... · CARE™ Lung Cancer AACR 2020 Update Target: EGFR Exon 20 Insertion Poziotinb

Antitumor Activity of Osimertinib, an Irreversible Mutant ... · EGFR exon 20 insertions (Ex20Ins) account for 4% to 10% of EGFR activating mutations in non–small cell lung cancer

Antitumor Activity of Osimertinib, an Irreversible Mutant ... · EGFR exon 20 insertions (Ex20Ins) account for 4% to 10% of EGFR activating mutations in non–small cell lung cancer

Biosensors and Bioelectronics - KAISTbel.kaist.ac.kr/extfiles/papers/20150827.pdf · Comprehensive detection of diverse exon 19 deletion mutations of EGFR in lung Cancer by a single

Biosensors and Bioelectronics - KAISTbel.kaist.ac.kr/extfiles/papers/20150827.pdf · Comprehensive detection of diverse exon 19 deletion mutations of EGFR in lung Cancer by a single

Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC€¦ · 15/05/2020  · manageable safety profile in heavily pretreated EGFR Exon20ins NSCLC patients. While amivantamab has

Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC€¦ · 15/05/2020  · manageable safety profile in heavily pretreated EGFR Exon20ins NSCLC patients. While amivantamab has

The challenge of targeting EGFR: experience with …...REVIEW The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer A.A. Armour and C.L. Watkins ABSTRACT:

The challenge of targeting EGFR: experience with …...REVIEW The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer A.A. Armour and C.L. Watkins ABSTRACT:

PowerPoint Presentation · Retinoblastoma WT QRX-421 Exon 12 Exon 13 Exon 14 Exon 12 Exon 14 In-frame Exon 11 Exon 14 Out of-frame No AON QRX-421 Exon 12 Exon 13 Exon 14 Erwin van

PowerPoint Presentation · Retinoblastoma WT QRX-421 Exon 12 Exon 13 Exon 14 Exon 12 Exon 14 In-frame Exon 11 Exon 14 Out of-frame No AON QRX-421 Exon 12 Exon 13 Exon 14 Erwin van

Frequent EGFR mutations in nonsmall cell lung cancer ...tyrosine kinase inhibitor, gefitinib, lung cancer, miliary carcinomatosis L ung cancer is the leading cause of cancer-related

Frequent EGFR mutations in nonsmall cell lung cancer ...tyrosine kinase inhibitor, gefitinib, lung cancer, miliary carcinomatosis L ung cancer is the leading cause of cancer-related

Reseptor Tirosin Kinase (Obat Gefitinib)

Reseptor Tirosin Kinase (Obat Gefitinib)

OPTIMIZACIÓN TRATAMIENTO ANTI-EGFR · KRAS exon 2 wt population1 0 6 12 18 24 30 36 42 48 54 28.4 20.2 0.0 0.2 0.6 0.8 ... Benefit with anti-EGFR Benefit without anti-EGFR Choice

OPTIMIZACIÓN TRATAMIENTO ANTI-EGFR · KRAS exon 2 wt population1 0 6 12 18 24 30 36 42 48 54 28.4 20.2 0.0 0.2 0.6 0.8 ... Benefit with anti-EGFR Benefit without anti-EGFR Choice